SB 431542
|
| رقم الكتالوجGC11545 |
SB-431542, a small molecule inhibitor of the type I TGF-β receptor, blocks intracellular mediators of TGF-1 signaling, which leads to decreased TGF-β1–mediated proliferation, cytokines and collagen expression.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 301836-41-9
Sample solution is provided at 25 µL, 10mM.
SB-431542, a small molecule inhibitor of the type I TGF-β receptor, blocks intracellular mediators of TGF-1 signaling, which leads to decreased TGF-β1–mediated proliferation, cytokines and collagen expression. In clinical settings, SB-431542 is widely used to treat respiratory asthma, and inhibits proliferation and synthesis of adventitial fibro in the process of pulmonary vascular remodeling.[1]
In vitro study indicated that SB-431542 is able to inhibit ALK5 with an IC50 of 94 nM and other type I receptors, such as ALK4. Although SB-431542 inhibited ALK4 with an IC50 of 140 nM. Moreover, SB-431542 inhibited TGF-β1–induced collagen Iα1 and PAI-1 mRNA with IC50 values of 60 and 50 nM, respectively. In addition, SB-431542 inhibited TGF-β1–induced fibronectin mRNA and protein with IC50 values of 62 and 22 nM, respectively. These data demonstrate for the first time that ALK5 activity is required for TGF-β1 regulation of extracellular matrix markers FN, collagen Iα1, and PAI-1 mRNA.[1]
In vivo study demonstrated that SB-431542 has the capacity to inhibit TGF-β1-induced gene expression. SB-431542 is recognized as a important inhibitor of the TGF-β1 receptors in blocking TGF-β1/Smads signal pathways in vascular remodeling. Moreover, hypoxia-induced vascular remodeling can significantly increase the amount of cytokines and collagen in vascular adventitia. However, after the treatment of SB-431542, attenuation of the fibrosis promoting effects of TGF-β1, including TGF-β1-induced cell proliferation, cell motility, cell migration and cell synthesis were observed. Therefore, it is significant to the identify the potential of SB-431542 for the treatment of hypoxia-induced pulmonary hypertension.[2]
References:
[1]. Laping NJ, et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol. 2002 Jul;62(1):58-64.
[2]. Yuan W, et al. SB-431542, a specific inhibitor of the TGF-β type I receptor inhibits hypoxia-induced proliferation of pulmonary artery adventitial fibroblasts. Pharmazie. 2016 Feb;71(2):94-100.
| Kinase experiment [1]: | |
|
Preparation Method |
The kinase domain without the GS region was cloned and expressed as a GST fusion protein. Expressing the protein without the GS domain, which has been shown to regulate the kinase activity, creates a constitutively active kinase that is able to phosphorylate GST-Smad3. Test the effects of SB-431542 on ALK5 and ALK4 kinase activity with GST-Smad3 as substrate. |
|
Reaction Conditions |
The Kinase assays were performed with 65 nM GSTALK5 and 184 nM GST-Smad3 in 50 mM HEPES, 5 mM MgCl2, 1 mM CaCl2, 1 mM dithiothreitol, and 3 μM ATP. Reactions were incubated with 0.5 μCi of [33P]γATP for 3 h at 30°C. |
|
Applications |
SB-431542 is a selective ALK5 inhibitor with little activity against p38 MAPK. SB-431542 also inhibits ALK4 activity. Which is consistent with the degree of homology between these kinases, such that ALK4 is the closest related kinase to ALK5. This data clearly demonstrated that SB-431542 is a potent and selective inhibitor of ALK5 and ALK4, with slightly higher selectivity for ALK5. |
| Cell experiment [1]: | |
|
Cell lines |
Renal proximal tubule epithelial cells (RPTEC) |
|
Preparation Method |
Cells were grown in Earle’s minimum essential medium supplemented with 10% fetal calf serum, penicillin (5 units/ml), and streptomycin (5 ng/ml). Cells were serum-starved for 24 h before treatment. |
|
Reaction Conditions |
Cells were treated with TGF-β1 (5 ng/ml) plus increasing concentrations of SB-431542 (50, 250, 500, and 700 nM). |
|
Applications |
SB-431542 could be used to evaluate whether ALK5 activity is required for TGF-β1-induced translocation of Smad3. SB-431542 at a concentration of 1 μM significantly reduced the TGF-β1-induced nuclear accumulation of Smad proteins. Thus, SB-431542 selectively inhibits TGF-β1–induced Smad translocation without affecting BMP-induced Smads. |
| Animal experiment [2]: | |
|
Animal models |
Male Sprague-Dawley rats aged 5 weeks, weighing 200-220 g |
|
Preparation Method |
Rats lived in air served as control groups, and rats lived in an air condition incubator containing 10% O2 to simulate chronic hypoxia animal model, and served as model groups. Model groups were treated with daily intraperitoneal injections of the SB-431542 for 28 days. |
|
Dosage form |
10 mg/kg; 20 mg/kg |
|
Applications |
SB-431542 inhibited the proliferative activity as a function of exposure time and concentration. Treated rats with SB-431542 caused more pathological changes in vascular adventitia, and the severity of the changes varied from slight to moderate depending on concentrations. In addition, the pulmonary arteries in the hypoxia-induced model groups had greater amounts of collagen fibers than that of the control groups. In comparison, collagen fibers were significantly reduced after treatment with SB-431542 (P < 0.01). |
|
References: [1]. Laping NJ, et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol. 2002 Jul;62(1):58-64. [2]. Yuan W, et al. SB-431542, a specific inhibitor of the TGF-β type I receptor inhibits hypoxia-induced proliferation of pulmonary artery adventitial fibroblasts. Pharmazie. 2016 Feb;71(2):94-100. |
|
| Cas No. | 301836-41-9 | SDF | |
| Chemical Name | 4-[4-(1,3-benzodioxol-5-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide | ||
| Canonical SMILES | C1OC2=C(O1)C=C(C=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5 | ||
| Formula | C22H16N4O3 | M.Wt | 384.39 |
| الذوبان | ≥ 19.2mg/mL in DMSO, ≥ 10.06 mg/mL in EtOH with ultrasonic | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6015 mL | 13.0076 mL | 26.0152 mL |
| 5 mM | 0.5203 mL | 2.6015 mL | 5.203 mL |
| 10 mM | 0.2602 mL | 1.3008 mL | 2.6015 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *